Doctors who specialize in the treatment of multiple sclerosis are conducting a clinical research study of an investigational drug for relapsing-remitting multiple sclerosis (RRMS) that is taken by mouth, rather than injected. If you have RRMS, you may be able to participate.

As you may know, the currently available medications for RRMS are Avonex®, Rebif®, Betaseron®, Novantrone®, Tysabri®, and Copaxone®. Studies have shown that these medications are effective in decreasing the rate and severity of relapses (as well as, in some cases, decreasing the risk that a disability caused by MS may progress).

However, all of the current RRMS medications also have the potential to cause some problematic side effects, such as flu-like symptoms and/or injection-site reactions. And, all of the current RRMS medications are injected – either under the skin, into the muscle, or into the vein – causing pain and, potentially, reactions on the body where they are injected.

Because of these concerns, medical researchers are working to develop oral treatments (treatments that are taken by mouth) that may reduce or eliminate these side effects.

To learn more – and to find out if you may be eligible to participate – click here.

A clinical research study of an investigational drug for MS that is taken by mouth.

Doctors who specialize in the treatment of multiple sclerosis are conducting FREEDOMS II: a clinical research study of the safety and effectiveness of an investigational oral drug for MS.

This investigational drug is currently being studied in people with MS to determine if it can:

• Decrease the rate and severity of relapse (worsening of symptoms)
• Decrease the risk that a disability caused by MS may progress
• Reduce the inflammatory activity in the body related to MS that may be a potential cause of relapses

Because the investigational drug is different from current medications, it is hoped that it won’t have some of the side effects that are often associated with current treatments, such as flu-like symptoms.

And, because the investigational drug is designed to be taken by mouth, there is no potential for it to cause injection-site reactions.

About study participation

Everyone who participates in this clinical research study receives the following (at no cost):

• Study-related care and monitoring from a doctor who specializes in the treatment of multiple sclerosis.
• Study drug – the investigational drug or a placebo. (Everyone who participates in this study has the same 2 in 3 chance of receiving the investigational drug.)

Participants who complete their study participation may be eligible to enter a long-term extension of the study, during which all patients will receive the investigational drug and study-related care and monitoring (at no cost).

To learn more – and to find out if you may be eligible to participate – click here.

How can I learn more?

If you are 18 to 55 years of age and have relapsing-remitting multiple sclerosis, the FREEDOMS II clinical research study may offer you an option worth considering.

To learn more – and to find out if you may be eligible to participate in this clinical research study – please visit our Web site: www.MSclinicaltrials.com

Thank you.